Vertex Pharmaceuticals stock falls after pain drug fails in Phase 2 study
SUNNYVALE, Calif.—Intuitive Surgical Inc. (NASDAQ:ISRG), a medical technology giant with a market capitalization of $211 billion and currently trading near its 52-week high, saw its Executive Vice President and Chief Medical (TASE:PMCN) Officer Myriam Curet recently sell shares of the company’s common stock, according to a recent SEC filing. On February 11, Curet sold 408 shares at an average price of $589.75 per share, totaling $240,618.
This transaction was conducted under a trading plan that complies with SEC Rule 10b5-1, which allows company insiders to set up a predetermined plan to sell shares at a later date, helping to avoid potential accusations of insider trading.
In addition to the sale, Curet engaged in other transactions on February 10. She acquired 838 shares through the vesting of Restricted Stock Units (RSUs), which converted into common stock at no cost. Furthermore, 430 shares were withheld to cover tax obligations at a price of $582.98 per share, amounting to $250,681.
Following these transactions, Curet holds a total of 353 shares of Intuitive Surgical common stock.
In other recent news, Intuitive Surgical has been the focus of several analyst firms following the company’s strong fourth quarter performance of 2024. RBC Capital Markets maintained an Outperform rating with a price target of $641, highlighting the company’s 10% and 24% beat on revenue and earnings per share (EPS), respectively. The firm also noted the company’s projected 13-16% year-over-year increase in procedure volume for 2025.
Piper Sandler analyst Adam Maeder increased the price target on Intuitive Surgical shares to $670, maintaining an Overweight rating. The firm’s updated financial model anticipates revenue growth of 14.6% year-over-year to $9.571 billion and adjusted EPS of $8.05 for 2025. Oppenheimer, however, maintained a Perform rating, expressing cautious outlook due to concerns about market saturation and the value proposition of the new da Vinci (EPA:SGEF) 5 system.
Bernstein analysts reiterated an Outperform rating and a $700 price target, highlighting the company’s strong financial performance in the last quarter. They also noted the company’s conservative profit and loss guidance for 2025. Lastly, Truist Securities increased its price target to $666, maintaining a Buy rating, and indicated that Intuitive Surgical is well-positioned to maintain a mid-to-high-teens revenue and profit compound annual growth rate over the next two to three years. These are recent developments, and it’s important for investors to stay updated on the company’s ongoing performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.